drugset / Trial / NCT06613152
HS-IT201 Injection in the Treatment of Advanced Solid Tumors
Phase 0
Not yet recruiting
9 enrolled
Qingdao Sino-Cell Biomedicine Co., Ltd.
The Affiliated Hospital of Qingdao University · collab
NaSingle-groupOpen-labelTreatment
Summary
Single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT201) after lymphodepletion preparative with fludarabine and cyclophosphamide regimen, followed by IL-2, for the treatment of patients with advanced solid tumor.
Timeline
- Start
- 2024-10
- Primary completion
- 2026-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-IT201 | Cell therapy | 5e+09 cells | Intravenous |
| Subject | HS-IT201 | Cell therapy | 4e+10 cells | Intravenous |